Диссертация (1139510), страница 55
Текст из файла (страница 55)
Neuropsychopharmacology. 2011Jul;36(8):1644-55.292. Pituch KA and Stevens JP: Applied multivariate statistics for the socialsciences. Sixth edition. New York, NY US: Routledge/Taylor & Francis Group;2016.293. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter genepromoter polymorphism (5-HTTLPR) association with antidepressant efficacy. EurNeuropsychopharmacol.
2012 Apr;22(4):239-58.294. Porcelli S., Drago A., Fabbri C., Gibiino S., Calati R., Serretti A.Pharmacogenetics of antidepressant response. J Psychiatry Neurosci2011;36(2):87-113.295. Pratt L, Brody D, Gu Q. Antidepressant use in persons aged 12 and over:United States, 2005–2008. NCHS Data Brief. 2011;76:1–8.296. Prieto-Alhambra D, Petri H, Goldenberg JSB, Khong TP, Klungel OH,Robinson NJ, et al.
Excess risk of hip fractures attributable to the use ofantidepressants in five European countries and the USA. OsteoporosisInt. 2014;25(3):847–855. doi: 10.1007/s00198-013-2612-2.297. Primo de Carvalho Alves L, Pio de Almeida Fleck M, Boni A, Sica da RochaN. The Major Depressive Disorder Hierarchy: Rasch Analysis of 6 items of theHamilton Depression Scale Covering the Continuum of Depressive Syndrome.Vrana KE, ed.
PLoS ONE. 2017;12(1):e0170000.291298. Psaltopoulou T., Sergentanis T.N., Panagiotakos D.B. et al. Mediterraneandiet, stroke, cognitive impairment, and depression: a metaanalysis // Ann. Neurol.2013. Vol. 74. P. 580–591299. Raison CL., Capuron L., Miller AH.Cytokines sing the blues:inflammation and the pathogenesis of depression. Trends Immunol. 2006 January;27(1): 24–31300. Rapaport MH , Gharabawi GM , Canuso CM , Mahmoud RA , Keller MB ,Bossie CA , et al . 2006 . Effects of risperidone augmentation in patients withtreatment-resistant depression: results of open-label treatment followed by doubleblind continuation . Neuropsychopharmacology 31 : 2505 – 2513 .301.
Reich JH. Effect of DSM-III personality disorders on outcome of tricyclicantidepressant-treated nonpsychotic outpatients with major or minor depressivedisorder. Psychiatry Res. 1990;32:175-181.302. Ripke S, Daly J, Lewis CM, Lin D, Wray NR, Neale B, et al. A megaanalysis of genome-wide association studies for major depressive disorder. MolPsychiatry. 2013;18:497–511.
1303. Rising K, Bacchetti P, Bero L: Reporting bias in drug trials submitted to theFood and Drug Administration: a review of publication and presentation. PLoSMed 2008;5:e217.304. Roberts RL, Joyce PR, Mulder RT, et al. A common P-glycoproteinpolymorphism is associated with nortriptyline-induced postural hypotension inpatients treated for major depression. Pharmacogenomics J 2002;2:191-6.305. Roest AM, Thombs BD, Grace SL, Stewart DE, Abbey SE, de Jonge P:Somatic/affective symptoms, but not cognitive/affective symptoms, of depressionafter acute coronary syndrome are associated with 12-month all-cause mortality. JAffect Disord 2011, 131:158-163.306. Rosenhagen MC, Uhr M.The clinical impact of ABCB1 polymorphisms onthe treatment of psychiatric diseases.
Curr Pharm Des. 2011;17(26):2843-51.307. Rotermann M, Sanmartin C, Hennessy D, Arthur M. Prescription medicationuse by Canadians aged 6 to 79. Health Rep. 2014;25(6):3–9.308. Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, etal. Combining medications to enhance depression outcomes (CO-MED): acute andlong-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168(7): 689-701309. Rush AJ, Warden D, Wisniewski SR, Fava M, Trivedi MH, Gaynes BN etal. STAR*D: revising conventional wisdom.
CNS Drugs 2009; 23: 627–647.310. Rush AJ. Combining antidepressant medications: a good idea? Am JPsychiatry. 2010; 167(3): 241-243.292311. Rush AJ: Limitations in efficacy of antidepressant monotherapy. J ClinPsychiatry 2007, 68(Suppl 10):8–10. 7.312. Rush AJ: The varied clinical presentations of major depressive disorder. JClin Psychiatry 2007, 68:4-10.313. Russell JM, Koran LM, Rush J, et al. Effect of concurrent anxiety onresponse to sertraline and imipramine in patients with chronic depression.
DepressAnxiety. 2001;13:18-27.314. Sáiz PA, García-Portilla MP, Arango C, Morales B, Arias B, Corcoran P,Fernández JM, Alvarez V, Coto E, Bascarán MT, Bousoño M, Fañanas L, Bobes J.Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor(DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data froman association study. Prog Neuropsychopharmacol Biol Psychiatry.
2010 Feb 1;34(1):26-31.315. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-relatedpharmacokinetics and pharmacodynamics. Biol Pharm Bull. 2002 Nov;25(11):1391-400.316. Samer C.F., Ing Lorenzini K., Rollason V., Daali Y., Desmeules J.A.Applications of CYP450 Testing in the Clinical Setting Mol Diagn Ther.
2013June; 17(3): 165–184.317. Sanacora, G., Treccani, G., and Popoli, M. (2012). Towards a glutamatehypothesis of depression: an emerging frontier of neuropsychopharmacology formood disorders. Neuropharmacology 62, 63–77.318. Sato T, Hirano S, Narita T, et al. Temperament and character inventorydimensions as a predictor of response to antidepressant treatment in majordepression. J Affect Disord. 1999;56:153-161.319. Saung WT, Narasimhan S, Lohoff FW.
Lack of influence of DAT1 andDRD2 gene variants on antidepressant response in generalized anxiety disorder.Hum Psychopharmacol. 2014 Jul;29(4):316-21.320. Schmittmann VD, Cramer AO, Waldorp LJ, Epskamp S, Kievit RA,Borsboom D. Deconstructing the construct: A network perspective onpsychological phenomena. New Ideas in Psychology. 2013;31(1):43–53.321. Scholes S, Faulding S, Mindell J.
Use of prescribed medicines. NHS HealthSurvey for England. 2013; Chapter 5. https://digital.nhs.uk/media/25813/HealthSurvey-for-England-2013-Chapter-5-Prescribed-medicines/Any/HSE2013-Ch5pres-meds.322. Scott S.A., Sangkuhl K., Shuldiner A.R., Hulot J.S., et al. PharmGKBsummary: very important pharmacogene information for cytochrome P450, family2932, subfamily C, polypeptide 19.
Pharmacogenetics and genomics. 2012;22(2):159–65.323. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, RodenDM, Klein TE, Shuldiner AR. Clinical Pharmacogenetics ImplementationConsortium. Review Clinical Pharmacogenetics Implementation Consortiumguidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogreltherapy. Clin Pharmacol Ther. 2011 Aug; 90(2):328-32.;324. Serretti A, Kato M, De Ronchi D, et al. Meta-analysis of serotonintransporter gene promoter polymorphism (5-HTTLPR) association with selectiveserotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry.2007;12:247–57325.
Serretti A, Olgiati P, Bajo E, Bigelli M, De Ronchi D. A model toincorporate genetic testing (5-HTTLPR) in pharmacological treatment of majordepressive disorders. World J Biol Psychiatry. 2011 Oct;12(7):501-15.326. Serretti A. Genetics and pharmacogenetics of mood disorders. Psychiatr. Pol.2017; 51(2): 197–203.327. Shelton RC , Tollefson GD , Tohen M , Stahl S , Gannon KS , Jacobs TG ,et al . 2001 . A novel augmentation strategy for treating resistant major depression .Am J Psychiatry 158 : 131 – 134 .328. Shelton RC , Williamson DJ , Corya SA , Sanger TM , Van Campen LE ,Case M , et al . 2005 .
Olanzapine/fl uoxetine combination for treatment-resistantdepression: a controlled study of SSRI and nortriptyline resistance . J ClinPsychiatry 66 : 1289 – 1297 .329. Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, Scheftner WA, etal. Genome-wide association study of recurrent early-onset major depressivedisorder. Mol Psychiatry. 2011;16:193–201.330.
Si T, Wang P. When is antidepressant polypharmacy appropriate in thetreatment of depression? Shanghai Arch Psychiatry. 2014 Dec; 26(6):357-9.331. Simon GE, Heiligenstein JH, Grothaus L, Katon W, Revicki D. Shouldanxiety and insomnia influence antidepressant selection: a randomized comparisonof fluoxetine and imipramine.
J Clin Psychiatry. 1998;59:49-55.332. Simon GE. Social and economic burden of mood disorders. BiolPsychiatry 2003;54:208–15.333. Singh AB, Bousman CA, Ng CH, Byron K, Berk M. ABCB1polymorphism predicts escitalopram dose needed for remission in majordepression. Transl Psychiatry.
2012 November; 2(11): e198.334. Smith DF. Quest for biomarkers of treatment-resistant depression: shiftingthe paradigm toward risk. Front Psychiatry. 2013;4:57.294335. Smits K, Smits L, Peeters F, et al. Serotonin transporter polymorphisms andthe occurrence of adverse events during treatment with selective serotonin reuptakeinhibitors. Int Clin Psychopharmacol. 2007;22:137–43.336. Smits KM, Smits LJM, Peeters FPML, Schouten JSAG, Janssen RGJH,Smeets HJM, Van Os J, Prins MH.
The influence of 5-HTTLPR and STin2polymorphisms in the serotonin transporter gene on treatment effect of selectiveserotonin reuptake inhibitors in depressive patients. Psychiatr Genet. 2008;11:184–190.337. Sonawalla S, Papakostas GI, Petersen T, et al. Elevated cholesterol levels inmajor depressive disorder associated with non-response to fluoxetine treatment.Psychosomatics. 2002;43:310-316.338. Spijker J, de Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen WA. Durationof major depressive episodes in the general population: results from TheNetherlands Mental Health Survey and Incidence Study (NEMESIS). Br JPsychiatry.
2002 Sep; 181():208-13339. Staeker J, Leucht S, Laika B, Steimer W. Polymorphisms in SerotonergicPathways Influence the Outcome of Antidepressant Therapy in PsychiatricInpatients. Genet Test Mol Biomarkers. 2013 Nov 5. [Epub ahead of print].340. Stahl SM, Lee-Zimmerman C, Cartwright S, Morrissette DA. Serotonergicdrugs for depression and beyond. Curr Drug Targets. 2013 May 1;14(5):578-85.341. Steinert C, Hofmann M, Kruse J et al. The prospective long-term course ofadult depression in general practice and the community. A systematic literaturereview. J Affect Disord 2014;152–154:65–75.342.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
